- Home
- CPOP vs APRE Comparison
CPOP vs APRE Comparison
Compare CPOP & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPOP
- APRE
- Stock Information
- Founded
- CPOP 2007
- APRE 2006
- Country
- CPOP China
- APRE United States
- Employees
- CPOP N/A
- APRE N/A
- Industry
- CPOP Services-Misc. Amusement & Recreation
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPOP Consumer Discretionary
- APRE Health Care
- Exchange
- CPOP Nasdaq
- APRE Nasdaq
- Market Cap
- CPOP 17.9M
- APRE 21.3M
- IPO Year
- CPOP 2021
- APRE 2019
- Fundamental
- Price
- CPOP $1.21
- APRE $2.92
- Analyst Decision
- CPOP
- APRE Strong Buy
- Analyst Count
- CPOP 0
- APRE 2
- Target Price
- CPOP N/A
- APRE $15.50
- AVG Volume (30 Days)
- CPOP 99.7K
- APRE 13.3K
- Earning Date
- CPOP 11-29-2024
- APRE 11-07-2024
- Dividend Yield
- CPOP N/A
- APRE N/A
- EPS Growth
- CPOP N/A
- APRE N/A
- EPS
- CPOP N/A
- APRE N/A
- Revenue
- CPOP $47,381,918.00
- APRE $1,310,839.00
- Revenue This Year
- CPOP N/A
- APRE $116.72
- Revenue Next Year
- CPOP N/A
- APRE N/A
- P/E Ratio
- CPOP N/A
- APRE N/A
- Revenue Growth
- CPOP 155.52
- APRE 130.31
- 52 Week Low
- CPOP $0.91
- APRE $2.15
- 52 Week High
- CPOP $9.67
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- CPOP 48.70
- APRE 34.50
- Support Level
- CPOP $1.18
- APRE $2.87
- Resistance Level
- CPOP $1.45
- APRE $3.35
- Average True Range (ATR)
- CPOP 0.08
- APRE 0.32
- MACD
- CPOP 0.00
- APRE -0.12
- Stochastic Oscillator
- CPOP 17.54
- APRE 4.50
About CPOP Pop Culture Group Co. Ltd
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from our Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.